On June 27th, Gelon Hui reported that Junshengtai Medicine-B (02511.HK) announced that the company's independently developed intestinal and hepatic anti-inflammatory and metabolic regulator HTD1801 (berberine) has completed patient enrollment in two phase III clinical registration trials for type 2 diabetes (T2DM) patients.
The two phase III registration trials are as follows: HTD1801.PCT105: A multicenter, randomized, double-blind, placebo-controlled study (SYMPHONY-1) assessing the efficacy and safety of HTD1801 in type 2 diabetes patients with poor blood sugar control after diet and exercise intervention.
HTD1801.PCT106: A multicenter, randomized, double-blind, placebo-controlled study (SYMPHONY-2) evaluating the efficacy and safety of HTD1801 in type 2 diabetes patients with poor glycemic control on metformin.
In these two trials, the effects of HTD1801 on glycated hemoglobin and glucose metabolism, blood lipids, liver damage/inflammation markers, and inflammation indicators of T2DM patients will be evaluated.